A Phase II Study to Investigate the Efficacy of Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Number of patients not requiring additional immunosuppression
The primary endpoint is met if at least 1 of the 5 first patients and 3 of a total of 11 patient will reach day 100 after transplant without additional immunsuppressive drug treatment
day 100 after transplant
Yes
Christoph Scheid, MD PhD
Principal Investigator
University of Cologne
Germany: Federal Institute for Drugs and Medical Devices
Uni-Koeln-1430
NCT01283776
March 2011
February 2012
Name | Location |
---|